Should asthma guidelines be rewritten for initial controller therapy: a 2 year randomized pragmatic equivalence trial of leukotriene antagonists (LTRAs) and inhaled corticosteroids (ICS) in primary care

D. Price, E. Sims, D. Freeman, L. Kemp, S. Musgrave, R. Gilbert, A. Blyth, J. Ayres, L. Juniper, J. Murdoch, I. Harvey (Aberdeen, Norwich, United Kingdom; Hamilton, Canada)

Source: Annual Congress 2008 - Rationale of self-education in asthma therapy

Session: Rationale of self-education in asthma therapy
Session type: Oral Presentation
Number: 4429

Disease area: Airway diseases, Paediatric lung diseases

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
D. Price, E. Sims, D. Freeman, L. Kemp, S. Musgrave, R. Gilbert, A. Blyth, J. Ayres, L. Juniper, J. Murdoch, I. Harvey (Aberdeen, Norwich, United Kingdom; Hamilton, Canada). Should asthma guidelines be rewritten for initial controller therapy: a 2 year randomized pragmatic equivalence trial of leukotriene antagonists (LTRAs) and inhaled corticosteroids (ICS) in primary care. Eur Respir J 2008; 32: Suppl. 52, 4429

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

Should guidelines be revised for add-on therapy in asthma? A 2 year randomized pragmatic equivalence trial of leukotriene antagonists (LTRAs) and long-acting beta agonists (LABAs) with inhaled corticosteroids (ICS) in primary care Source: Annual Congress 2008 - Wider aspects of managing respiratory disease in primary care Year: 2008
Reframing asthma and inhaled corticosteroids (ICS) to modify treatment beliefs: an online randomised controlled trial Source: International Congress 2018 – Educational tools to improve your practice Year: 2018
Real-life use and impact of inhaled steroids (ICS) and leukotriene receptor antagonists (LTRA) monotherapy in children with asthma Source: Annual Congress 2010 - Paediatric asthma treatment and monitoring Year: 2010
LATE-BREAKING ABSTRACT: A dose-ranging study of dupilumab in patients (pts) with uncontrolled asthma despite use of inhaled corticosteroids plus a long-acting beta-agonist (ICS/LABA): Final data Source: International Congress 2015 – Hot topics on airway diseases: new horizons in treatment Year: 2015
First line maintenance therapy for asthma: an observational study comparing inhaled corticosteroid monotherapy to combination inhaled corticosteroid/long acting beta agonist therapy in UK general practice Source: Annual Congress 2007 - Traditional and novel approaches to assess and achieve asthma control Year: 2007
Factors influencing the relative effect of leukotriene receptor antagonists (LTRA) and inhaled corticosteroids (ICS) as monotherapy in persistent asthma: A systematic review Source: Annual Congress 2011 - Asthma management and response Year: 2011
Safety of long-acting β-agonist (LABA) withdrawal in patients in two clinical asthma trials Source: Annual Congress 2012 - Different ways to phenotype asthma Year: 2012
Step-up of asthma therapy: an observational study comparing increased inhaled corticosteroid dosage to combination inhaled corticosteroid/long acting beta agonist therapy in UK general practice Source: Annual Congress 2007 - Traditional and novel approaches to assess and achieve asthma control Year: 2007
Efficacy and safety of as-needed corticosteroid plus fast or short-acting beta-agonists monotherapy in patients with mild asthma: a meta-analysis of randomised controlled trials. Source: Virtual Congress 2020 – Inhaled corticosteroids and bronchodilator studies in asthma Year: 2020
An electronic patient decision aid comparing as-needed budesonide-formoterol combination to regular use of inhaled corticosteroid (ICS) in mild asthma: a rapid-cycle design study Source: Virtual Congress 2021 – Therapies for respiratory diseases in primary care and COVID - 19 Year: 2021
Phase III trial of tiotropium as add-on therapy to low-dose inhaled corticosteroids for patients with symptomatic mild persistent asthma: Design and planned analyses Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013
Health care resource utilization following addition of montelukast or salmeterol to fluticasone in patients with inadequately controlled asthma (IMPACT trial) Source: Eur Respir J 2004; 24: Suppl. 48, 127s Year: 2004
Treatment with inhaled corticosteroids (ICS), smoking and asthma control in real clinical practice Source: Annual Congress 2010 - Pharmacological treatment in primary care Year: 2010
Description of a randomised controlled trial of inhaled corticosteroid/fast-onset LABA reliever therapy in mild asthma Source: Eur Respir J 2016; 47: 981-984 Year: 2016
Treatment with inhaled corticosteroids (ICS) in patients with COPD: possible way of optimisation Source: Annual Congress 2009 - Drug effects in COPD Year: 2009
Efficacy of mometasone/indacaterol/glycopyrronium (MF/IND/GLY) on lung function and exacerbations in patients with inadequately controlled asthma with high-dose ICS/LABA therapy (on GINA step 5) prior to study entry: Results from IRIDIUM study Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence Year: 2021
A new user cohort study comparing the risk of pneumonia in inhaled corticosteroid (ICS) vs. long-acting bronchodilator (LABD) regimens in COPD Source: Annual Congress 2013 –Risk factors for COPD and lung function decline Year: 2013
Efficacy and safety of BI 671800, an oral CRTH2 antagonist, as add on therapy in poorly controlled asthma patients prescribed an inhaled corticosteroid Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma Year: 2012
Efficacy and safety of BI 671800, an oral CRTH2 antagonist, as add on therapy in poorly controlled asthma patients prescribed an inhaled corticosteroid Source: Annual Congress 2012 - New bronchodilators and other novel drugs for asthma and COPD Year: 2012
Inhaled corticosteroid (ICS) and long-acting beta2-agonist (LABA) combination vs. high doses of ICS: efficacy and safety in patients (pts) with uncontrolled occupational asthma Source: International Congress 2017 – Techniques to treat asthma Year: 2017